Am I missing anything? Is this the right decision?

Can I show this data?

Am I too late?

Find clarity in your investment decision-making.

Manage your portfolio for sustainable growth

and regulatory alignment

with the ultimate blend of powerful AI and

industry expertise.

Reduce risk, meet your sustainability goals and push the boundaries of possibilities based on

facts, not opinions.

Clarity AI scaling human decisions through tech.

Visit clarity.

And take action today.

The road to bringing a new medication to market is a long and expensive path.

And Sir John Bell, who's the chair of a British biotech firm called Munocor, knows this quite well.

It's usually, you know, it's 10, 12, 14 years, something like that.

And for a company that's starting out that's a long journey

because you have to raise money all the way along that journey to get to where you need to get to.

Immunocore got its start in Bell's lab more than 20 years ago. But as the company grew, they

needed to find investors. So first, they looked inside the UK. And so in about

2014, they raised a big a round from largely UK investors.

So they raised a lot of money then and set off on a journey to try and develop these drugs.

...